Search

Your search keyword '"Etra, Aaron"' showing total 18 results
Start Over Author "Etra, Aaron" Publisher american society of hematology
18 results on '"Etra, Aaron"'

1. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis

Author

Akahoshi, Yu, primary, Spyrou, Nikolaos, additional, Hoepting, Matthias, additional, Aguayo-Hiraldo, Paibel, additional, Ayuk, Francis Ayuketang, additional, Chanswangphuwana, Chantiya, additional, Choe, Hannah K, additional, Eder, Matthias, additional, Etra, Aaron M., additional, Grupp, Stephan A., additional, Hexner, Elizabeth O., additional, Hogan, William J, additional, Kitko, Carrie L., additional, Kraus, Sabrina, additional, Al Malki, Monzr M, additional, Merli, Pietro, additional, Qayed, Muna, additional, Reshef, Ran, additional, Schechter-Finkelstein, Tal, additional, Ullrich, Evelyn, additional, Vasova, Ingrid, additional, Wölfl, Matthias, additional, Zeiser, Robert, additional, Baez, Janna, additional, Beheshti, Rahnuma, additional, Eng, Gilbert W, additional, Gleich, Sigrun, additional, Kasikis, Stelios, additional, Katsivelos, Nikolaos, additional, Kowalyk, Steven, additional, Morales, George, additional, Young, Rachel, additional, DeFilipp, Zachariah, additional, Ferrara, James L.M., additional, Levine, John E, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

2. The utility of biomarkers in acute GVHD prognostication

Author

Spyrou, Nikolaos, primary, Akahoshi, Yu, additional, Ayuk, Francis, additional, Holler, Ernst, additional, Choe, Hannah, additional, Etra, Aaron, additional, Hogan, William J., additional, Rösler, Wolf, additional, Hexner, Elizabeth, additional, DeFilipp, Zachariah, additional, Reshef, Ran, additional, Chanswangphuwana, Chantiya, additional, Qayed, Muna, additional, Kraus, Sabrina, additional, Eder, Matthias, additional, Javorniczky, Nora Rebeka, additional, Grupp, Stephan A., additional, Kitko, Carrie L., additional, Merli, Pietro, additional, Aguayo-Hiraldo, Paibel, additional, Wölfl, Matthias, additional, Baez, Janna, additional, Beheshti, Rahnuma, additional, Eng, Gilbert, additional, Gleich, Sigrun, additional, Katsivelos, Nikolaos, additional, Khan, Alina, additional, Kowalyk, Steven, additional, Morales, George, additional, Young, Rachel, additional, Nakamura, Ryotaro, additional, Chen, Yi-Bin, additional, Levine, John E., additional, and Ferrara, James L. M., additional

Published
2023
Full Text
View/download PDF

3. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Author

Al Malki, Monzr M., primary, London, Kaitlyn, additional, Baez, Janna, additional, Akahoshi, Yu, additional, Hogan, William J., additional, Etra, Aaron, additional, Choe, Hannah, additional, Hexner, Elizabeth, additional, Langston, Amelia, additional, Abhyankar, Sunil, additional, Ponce, Doris M., additional, DeFilipp, Zachariah, additional, Kitko, Carrie L., additional, Adekola, Kehinde, additional, Reshef, Ran, additional, Ayuk, Francis, additional, Capellini, Alexandra, additional, Chanswangphuwana, Chantiya, additional, Eder, Matthias, additional, Eng, Gilbert, additional, Gandhi, Isha, additional, Grupp, Stephan, additional, Gleich, Sigrun, additional, Holler, Ernst, additional, Javorniczky, Nora Rebeka, additional, Kasikis, Stelios, additional, Kowalyk, Steven, additional, Morales, George, additional, Özbek, Umut, additional, Rösler, Wolf, additional, Spyrou, Nikolaos, additional, Yanik, Gregory, additional, Young, Rachel, additional, Chen, Yi-Bin, additional, Nakamura, Ryotaro, additional, Ferrara, James L. M., additional, and Levine, John E., additional

Published
2023
Full Text
View/download PDF

4. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

Author

Akahoshi, Yu, primary, Spyrou, Nikolaos, additional, Hogan, William J., additional, Ayuk, Francis, additional, DeFilipp, Zachariah, additional, Weber, Daniela, additional, Choe, Hannah K., additional, Hexner, Elizabeth O., additional, Rösler, Wolf, additional, Etra, Aaron M., additional, Sandhu, Karamjeet, additional, Yanik, Gregory A., additional, Chanswangphuwana, Chantiya, additional, Kitko, Carrie L., additional, Reshef, Ran, additional, Kraus, Sabrina, additional, Wölfl, Matthias, additional, Eder, Matthias, additional, Bertrand, Hannah, additional, Qayed, Muna, additional, Merli, Pietro, additional, Grupp, Stephan A., additional, Aguayo-Hiraldo, Paibel, additional, Schechter, Tal, additional, Ullrich, Evelyn, additional, Baez, Janna, additional, Beheshti, Rahnuma, additional, Gleich, Sigrun, additional, Kowalyk, Steven, additional, Morales, George, additional, Young, Rachel, additional, Kwon, Deukwoo, additional, Nakamura, Ryotaro, additional, Levine, John E., additional, Ferrara, James L. M., additional, and Chen, Yi-Bin, additional

Published
2023
Full Text
View/download PDF

5. Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Author

Etra, Aaron, primary, Capellini, Alexandra, additional, Alousi, Amin, additional, Al Malki, Monzr M., additional, Choe, Hannah, additional, DeFilipp, Zachariah, additional, Hogan, William J., additional, Kitko, Carrie L., additional, Ayuk, Francis, additional, Baez, Janna, additional, Gandhi, Isha, additional, Kasikis, Stelios, additional, Gleich, Sigrun, additional, Hexner, Elizabeth, additional, Hoepting, Matthias, additional, Kapoor, Urvi, additional, Kowalyk, Steven, additional, Kwon, Deukwoo, additional, Langston, Amelia, additional, Mielcarek, Marco, additional, Morales, George, additional, Özbek, Umut, additional, Qayed, Muna, additional, Reshef, Ran, additional, Rösler, Wolf, additional, Spyrou, Nikolaos, additional, Young, Rachel, additional, Chen, Yi-Bin, additional, Ferrara, James L. M., additional, and Levine, John E., additional

Published
2023
Full Text
View/download PDF

6. Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

Author

Capellini, Alexandra, primary, Etra, Aaron, additional, Alousi, Amin M, additional, Al Malki, Monzr M., additional, Choe, Hannah, additional, Defilipp, Zachariah, additional, Hogan, William J., additional, Kitko, Carrie Lynn, additional, Ayuk, Francis A., additional, Baez, Janna, additional, Gandhi, Isha, additional, Kasikis, Stelios, additional, Gleich, Sigrun, additional, Hexner, Elizabeth O., additional, Hoepting, Matthias, additional, Kapoor, Urvi, additional, Kowalyk, Steven, additional, Kwon, Deukwoo, additional, Langston, Amelia, additional, Mielcarek, Marco, additional, Morales, George, additional, Ozbek, Umut, additional, Qayed, Muna, additional, Reshef, Ran, additional, Roesler, Wolf, additional, Spyrou, Nikolaos, additional, Young, Rachel, additional, Chen, Yi-Bin, additional, Ferrara, James L.M., additional, and Levine, John E., additional

Published
2022
Full Text
View/download PDF

8. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

Author

Etra, Aaron, primary, Gergoudis, Stephanie, additional, Morales, George, additional, Spyrou, Nikolaos, additional, Shah, Jay, additional, Kowalyk, Steven, additional, Ayuk, Francis, additional, Baez, Janna, additional, Chanswangphuwana, Chantiya, additional, Chen, Yi-Bin, additional, Choe, Hannah, additional, DeFilipp, Zachariah, additional, Gandhi, Isha, additional, Hexner, Elizabeth, additional, Hogan, William J., additional, Holler, Ernst, additional, Kapoor, Urvi, additional, Kitko, Carrie L., additional, Kraus, Sabrina, additional, Lin, Jung-Yi, additional, Al Malki, Monzr, additional, Merli, Pietro, additional, Pawarode, Attaphol, additional, Pulsipher, Michael A., additional, Qayed, Muna, additional, Reshef, Ran, additional, Rösler, Wolf, additional, Schechter, Tal, additional, Van Hyfte, Grace, additional, Weber, Daniela, additional, Wölfl, Matthias, additional, Young, Rachel, additional, Özbek, Umut, additional, Ferrara, James L. M., additional, and Levine, John E., additional

Published
2022
Full Text
View/download PDF

9. Pathogenic Germline Variants in Multiple Myeloma

Author

Thibaud, Santiago, primary, Etra, Aaron, additional, Subaran, Ryan, additional, Soens, Zachry, additional, Newman, Scott, additional, Chen, Rong, additional, Chari, Ajai, additional, Cho, Hearn Jay, additional, Jagannath, Sundar, additional, Madduri, Deepu, additional, Melnekoff, David T., additional, Richard, Shambavi, additional, Richter, Joshua, additional, Sanchez, Larysa, additional, Huang, Kuan-lin, additional, Lagana, Alessandro, additional, Parekh, Samir, additional, and Onel, Kenan, additional

Published
2021
Full Text
View/download PDF

10. Prognostic Value of Elafin in Acute Graft-Versus-Host Disease

Author

Zewde, Makda Getachew, primary, Morales, George, additional, Gandhi, Isha, additional, Ozbek, Umut, additional, Aguayo-Hiraldo, Paibel, additional, Ayuk, Francis A., additional, Baez, Janna, additional, Chanswangphuwana, Chantiya, additional, Choe, Hannah, additional, DeFilipp, Zachariah, additional, Etra, Aaron, additional, Grupp, Stephan A., additional, Hexner, Elizabeth O., additional, Hogan, William J, additional, Javorniczky, Rebeka, additional, Kasikis, Stelios, additional, Kitko, Carrie Lynn, additional, Kowalyk, Steven, additional, Meedt, Elisabeth, additional, Merli, Pietro, additional, Nakamura, Ryotaro, additional, Qayed, Muna, additional, Reshef, Ran, additional, Roesler, Wolf, additional, Schechter-Finkelstein, Tal, additional, Weber, Daniela, additional, Wölfl, Matthias, additional, Yanik, Gregory A, additional, Young, Rachel, additional, Levine, John E., additional, Ferrara, James L., additional, and Chen, Yi-Bin, additional

Published
2021
Full Text
View/download PDF

11. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

Author

Gergoudis, Stephanie C., primary, DeFilipp, Zachariah, additional, Özbek, Umut, additional, Sandhu, Karamjeet S., additional, Etra, Aaron M., additional, Choe, Hannah K., additional, Kitko, Carrie L., additional, Ayuk, Francis, additional, Aziz, Mina, additional, Baez, Janna, additional, Ben-David, Kaitlyn, additional, Bunworasate, Udomsak, additional, Gandhi, Isha, additional, Hexner, Elizabeth O., additional, Hogan, William J., additional, Holler, Ernst, additional, Kasikis, Stelios, additional, Kowalyk, Steven M., additional, Lin, Jung-Yi, additional, Merli, Pietro, additional, Morales, George, additional, Nakamura, Ryotaro, additional, Reshef, Ran, additional, Rösler, Wolf, additional, Srinagesh, Hrishikesh, additional, Young, Rachel, additional, Chen, Yi-Bin, additional, Ferrara, James L. M., additional, and Levine, John E., additional

Published
2020
Full Text
View/download PDF

12. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease

Author

Srinagesh, Hrishikesh K., primary, Özbek, Umut, additional, Kapoor, Urvi, additional, Ayuk, Francis, additional, Aziz, Mina, additional, Ben-David, Kaitlyn, additional, Choe, Hannah K., additional, DeFilipp, Zachariah, additional, Etra, Aaron, additional, Grupp, Stephan A., additional, Hartwell, Matthew J., additional, Hexner, Elizabeth O., additional, Hogan, William J., additional, Karol, Alexander B., additional, Kasikis, Stelios, additional, Kitko, Carrie L., additional, Kowalyk, Steven, additional, Lin, Jung-Yi, additional, Major-Monfried, Hannah, additional, Mielke, Stephan, additional, Merli, Pietro, additional, Morales, George, additional, Ordemann, Rainer, additional, Pulsipher, Michael A., additional, Qayed, Muna, additional, Reddy, Pavan, additional, Reshef, Ran, additional, Rösler, Wolf, additional, Sandhu, Karamjeet S., additional, Schechter, Tal, additional, Shah, Jay, additional, Sigel, Keith, additional, Weber, Daniela, additional, Wölfl, Matthias, additional, Wudhikarn, Kitsada, additional, Young, Rachel, additional, Levine, John E., additional, and Ferrara, James L. M., additional

Published
2019
Full Text
View/download PDF

13. The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease

Author

Srinagesh, Hrishikesh, primary, Ozbek, Umut, primary, Kapoor, Urvi, primary, Ayuk, Francis Ayuketang, primary, Aziz, Mina D., primary, Ben-David, Kaitlyn, primary, Choe, Hannah K., primary, Defilipp, Zachariah, primary, Etra, Aaron, primary, Grupp, Stephan, primary, Hartwell, Matthew, primary, Hexner, Elizabeth O., primary, Hogan, William J, primary, Kitko, Carrie, primary, Kowalyk, Steven, primary, Lin, Jung-Yi, primary, Major-Monfried, Hannah, primary, Mielke, Stephan, primary, Merli, Pietro, primary, Morales, George, primary, Ordemann, Rainer, primary, Pulsipher, Michael A., primary, Qayed, Muna, primary, Reddy, Pavan, primary, Reshef, Ran, primary, Roesler, Wolf, primary, Sandhu, Karamjeet S., primary, Schechter-Finkelstein, Tal, primary, Shah, Jay, primary, Sigel, Keith, primary, Weber, Daniela, primary, Wölfl, Matthias, primary, Wudhikarn, Kitsada, primary, Young, Rachel, primary, Levine, John E., primary, and Ferrara, James L. M., primary

Published
2019
Full Text
View/download PDF

14. Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease

Author

Aziz, Mina D., primary, Shah, Jay, additional, Kapoor, Urvi, additional, Dimopoulos, Christina N., additional, Ayuk, Francis A., additional, Hogan, William J., additional, Schreiner, Elisabeth, additional, Choe, Hannah K., additional, Chen, Yi-Bin, additional, Hexner, Elizabeth O., additional, Etra, Aaron, additional, Merli, Pietro, additional, Roesler, Wolf, additional, Kitko, Carrie, additional, Qayed, Muna, additional, Wölfl, Matthias, additional, Mielke, Stephan, additional, Wudhikarn, Kitsada, additional, Nakamura, Ryotaro, additional, Ordemann, Rainer, additional, Pulsipher, Michael A., additional, Reshef, Ran, additional, Anand, Sarah, additional, Yanik, Gregory, additional, Morales, George, additional, Kowalyk, Steven, additional, Young, Rachel, additional, Kroeger, Nicolaus, additional, Schechter-Finkelstein, Tal, additional, Hartwell, Matthew, additional, Gergoudis, Stephanie, additional, Augustine, Allan, additional, Ozbek, Umut, additional, Levine, John E., additional, and Ferrara, James L.M., additional

Published
2018
Full Text
View/download PDF

15. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Author

Major-Monfried, Hannah, primary, Renteria, Anne S., additional, Pawarode, Attaphol, additional, Reddy, Pavan, additional, Ayuk, Francis, additional, Holler, Ernst, additional, Efebera, Yvonne A., additional, Hogan, William J., additional, Wölfl, Matthias, additional, Qayed, Muna, additional, Hexner, Elizabeth O., additional, Wudhikarn, Kitsada, additional, Ordemann, Rainer, additional, Young, Rachel, additional, Shah, Jay, additional, Hartwell, Matthew J., additional, Chaudhry, Mohammed S., additional, Aziz, Mina, additional, Etra, Aaron, additional, Yanik, Gregory A., additional, Kröger, Nicolaus, additional, Weber, Daniela, additional, Chen, Yi-Bin, additional, Nakamura, Ryotaro, additional, Rösler, Wolf, additional, Kitko, Carrie L., additional, Harris, Andrew C., additional, Pulsipher, Michael, additional, Reshef, Ran, additional, Kowalyk, Steven, additional, Morales, George, additional, Torres, Ivan, additional, Özbek, Umut, additional, Ferrara, James L. M., additional, and Levine, John E., additional

Published
2018
Full Text
View/download PDF

16. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.

Author

DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng G, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk F, Choe H, Etra A, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E, Ferrara JLM, Nakamura R, Levine JE, and Chen YB

Subjects
Humans, Male, Female, Middle Aged, Adult, Treatment Outcome, Nitriles therapeutic use, Pyrazoles therapeutic use, Pyrimidines therapeutic use, Aged, Acute Disease, Biomarkers, Young Adult, Adolescent, Hematopoietic Stem Cell Transplantation adverse effects, Graft vs Host Disease drug therapy, Graft vs Host Disease etiology, Algorithms
Abstract

Abstract: The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC) between 2016 and 2021. Sixty-two patients received ruxolitinib-based therapy, whereas 102 received other systemic agents. In agreement with prospective trials, ruxolitinib resulted in a higher day 28 (D28) overall response Frate than nonruxolitinib therapies (55% vs 31%, P = .003) and patients who received ruxolitinib had significantly lower nonrelapse mortality (NRM) than those who received nonruxolitinib therapies (point estimates at 2-year: 35% vs 61%, P = .002). Biomarker analyses demonstrated that the benefit from ruxolitinib was observed only in patients with low MAGIC algorithm probabilities (MAPs) at the start of second-line treatment. Among patients with a low MAP, those who received ruxolitinib experienced significantly lower NRM than those who received nonruxolitinib therapies (point estimates at 2-year: 12% vs 41%, P = .016). However, patients with high MAP experienced high NRM regardless of treatment with ruxolitinib or nonruxolitinib therapies (point estimates at 2-year: 67% vs 80%, P = .65). A landmark analysis demonstrated that the relationship between the D28 response and NRM largely depends on the MAP level at the initiation of second-line therapy. In conclusion, MAP measured at second-line systemic treatment for acute GVHD predicts treatment response and NRM. The outcomes of patients with high MAP are poor regardless of treatment choice, and ruxolitinib appears to primarily benefit patients with low MAP., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2024
Full Text
View/download PDF

17. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.

Author

Etra A, El Jurdi N, Katsivelos N, Kwon D, Gergoudis S, Morales G, Spyrou N, Kowalyk S, Aguayo-Hiraldo P, Akahoshi Y, Ayuk F, Baez J, Betts BC, Chanswangphuwana C, Chen YB, Choe H, DeFilipp Z, Gleich S, Hexner E, Hogan WJ, Holler E, Kitko CL, Kraus S, Al Malki M, MacMillan M, Pawarode A, Quagliarella F, Qayed M, Reshef R, Schechter T, Vasova I, Weisdorf D, Wölfl M, Young R, Nakamura R, Ferrara JLM, Levine JE, and Holtan S

Subjects
Humans, Male, Female, Middle Aged, Adult, Aged, Prognosis, Antigens, Neoplasm blood, Acute Disease, Adolescent, Young Adult, Graft vs Host Disease blood, Graft vs Host Disease diagnosis, Graft vs Host Disease etiology, Graft vs Host Disease mortality, Interleukin-1 Receptor-Like 1 Protein blood, Biomarkers blood, Pancreatitis-Associated Proteins blood, Algorithms, Amphiregulin blood, Hematopoietic Stem Cell Transplantation adverse effects
Abstract

Abstract: Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of 2 GI GVHD biomarkers (suppressor of tumorigenicity-2 [ST2] + regenerating family member 3 alpha [REG3α]) when measured at GVHD diagnosis are validated predictors of NRM risk but have never been assessed in the same patients using identical statistical methods. We measured the serum concentrations of ST2, REG3α, and AREG by enzyme-linked immunosorbent assay at the time of GVHD diagnosis in 715 patients divided by the date of transplantation into training (2004-2015) and validation (2015-2017) cohorts. The training cohort (n = 341) was used to develop algorithms for predicting the probability of 12-month NRM that contained all possible combinations of 1 to 3 biomarkers and a threshold corresponding to the concordance probability was used to stratify patients for the risk of NRM. Algorithms were compared with each other based on several metrics, including the area under the receiver operating characteristics curve, proportion of patients correctly classified, sensitivity, and specificity using only the validation cohort (n = 374). All algorithms were strong discriminators of 12-month NRM, whether or not patients were systemically treated (n = 321). An algorithm containing only ST2 + REG3α had the highest area under the receiver operating characteristics curve (0.757), correctly classified the most patients (75%), and more accurately risk-stratified those who developed Minnesota standard-risk GVHD and for patients who received posttransplant cyclophosphamide-based prophylaxis. An algorithm containing only AREG more accurately risk-stratified patients with Minnesota high-risk GVHD. Combining ST2, REG3α, and AREG into a single algorithm did not improve performance., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2024
Full Text
View/download PDF

18. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.

Author

Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara JLM, Levine JE, and Nakamura R

Subjects
Humans, Male, Female, Middle Aged, Adult, Retrospective Studies, Acute Disease, Hematopoietic Stem Cell Transplantation adverse effects, Adolescent, Aged, Biomarkers blood, Young Adult, Risk Factors, Graft vs Host Disease etiology, Graft vs Host Disease diagnosis
Abstract

Abstract: The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) or very good partial response (VGPR) within 4 weeks of treatment. The cumulative incidence of flares within 6 months was 22%, and flares were associated with a higher risk of nonrelapse mortality (NRM; adjusted hazard ratio [aHR], 4.84; 95% confidence interval [CI], 3.19-7.36; P < .001). Flares were more severe (grades 3/4, 41% vs 16%; P < .001) and had more frequent lower gastrointestinal (LGI) involvement (55% vs 32%; P < .001) than the initial GVHD. At CR/VGPR, elevated MAGIC biomarkers predicted the future occurrence of a flare, along with its severity and LGI involvement. In multivariate analyses, higher Ann Arbor (AA) biomarker scores at CR/VGPR were significant risk factors for flares (AA2 vs AA1: aHR, 1.81 [95% CI, 1.32-2.48; P = .001]; AA3 vs AA1: aHR, 3.14 [95% CI, 1.98-4.98; P < .001]), as were early response to initial treatment (aHR, 1.84; 95% CI, 1.21-2.80; P = .004) and HLA-mismatched unrelated donor (aHR, 1.74; 95% CI, 1.00-3.02; P = .049). MAGIC biomarkers also stratified the risk of NRM both at CR/VGPR and at the time of flare. We conclude that GVHD flares are common and carry a significant mortality risk. The occurrence of future flares can be predicted by serum biomarkers that may serve to guide adjustment and discontinuation of immunosuppression., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results